C. Touzeau, P. Moreau, and C. Dumontet, Monoclonal antibody therapy in multiple myeloma, Leukemia, vol.31, pp.1039-1086, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01795709

S. K. Kumar, M. A. Dimopoulos, E. Kastritis, E. Terpos, H. Nahi et al., Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

A. G. Letai, Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nat Rev Cancer, vol.8, pp.121-153, 2008.

A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, vol.19, pp.202-210, 2013.

A. W. Roberts, M. S. Davids, J. M. Pagel, B. S. Kahl, S. D. Puvvada et al., Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.374, pp.311-333, 2016.

M. S. Davids, A. W. Roberts, J. F. Seymour, J. M. Pagel, B. S. Kahl et al., Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma, J Clin Oncol J Am Soc Clin Oncol, vol.35, pp.826-859, 2017.

S. Derenne, B. Monia, N. M. Dean, J. K. Taylor, M. Rapp et al., Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-203, 2002.

S. Wuillème-toumi, N. Robillard, P. Gomez, P. Moreau, L. Gouill et al., Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.19, pp.1248-52, 2005.

J. Gong, T. Khong, D. Segal, Y. Yao, C. D. Riffkin et al., Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1, Blood, vol.128, pp.1834-1878, 2016.

P. Gomez-bougie and M. Amiot, Apoptotic machinery diversity in multiple myeloma molecular subtypes, Front Immunol, vol.4, p.467, 2013.

L. Bodet, E. Ménoret, G. Descamps, C. Pellat-deceunynck, R. Bataille et al., BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma, Br J Cancer, vol.103, pp.1808-1822, 2010.

L. Bodet, P. Gomez-bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, pp.3901-3911, 2011.

C. Touzeau, J. Ryan, J. Guerriero, P. Moreau, T. N. Chonghaile et al., BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.30, pp.761-765, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01411102

A. A. Morales, M. Kurtoglu, S. M. Matulis, J. Liu, D. Siefker et al., Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, pp.1329-1368, 2011.

N. Vandedonk, M. Kamphuis, M. Van-dijk, H. Borst, A. C. Bloem et al., Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein, Leukemia, vol.17, pp.211-220, 2003.

A. Z. Badros, O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres et al., Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients, J Clin Oncol J Am Soc Clin Oncol, vol.23, pp.4089-99, 2005.

A. A. Chanan-khan, R. Niesvizky, R. J. Hohl, T. M. Zimmerman, N. P. Christiansen et al., Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma, Leuk Lymphoma, vol.50, pp.559-65, 2009.

A. Paulus, K. Chitta, S. Akhtar, D. Personett, K. C. Miller et al., AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia, Br J Haematol, vol.164, pp.352-65, 2014.

S. Trudel, Z. H. Li, J. Rauw, R. E. Tiedemann, X. Y. Wen et al., Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015070) in multiple myeloma, Blood, vol.109, pp.5430-5438, 2007.

T. Oltersdorf, S. W. Elmore, A. R. Shoemaker, R. C. Armstrong, D. J. Augeri et al., An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.435, pp.677-81, 2005.

A. W. Roberts, J. F. Seymour, J. R. Brown, W. G. Wierda, T. J. Kipps et al., Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J Clin Oncol J Am Soc Clin Oncol, vol.30, pp.488-96, 2012.

J. F. Seymour, T. J. Kipps, B. Eichhorst, P. Hillmen, D. 'rozario et al., Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia, N Engl J Med, vol.378, pp.1107-1127, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01815999

D. Chiron, C. Dousset, C. Brosseau, C. Touzeau, S. Maïga et al., Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, pp.8750-8759, 2015.

C. D. Dinardo, K. W. Pratz, A. Letai, B. A. Jonas, A. H. Wei et al., Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study, Lancet Oncol, vol.19, pp.216-244, 2018.

C. D. Dinardo, C. R. Rausch, C. Benton, T. Kadia, N. Jain et al., Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol, vol.93, pp.401-408, 2018.

M. Konopleva, D. A. Pollyea, J. Potluri, B. Chyla, L. Hogdal et al., Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia, Cancer Discov, vol.6, pp.1106-1123, 2016.

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.28, pp.210-212, 2014.

E. A. Punnoose, J. D. Leverson, F. Peale, E. R. Boghaert, L. D. Belmont et al., Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models, Mol Cancer Ther, vol.15, pp.1132-1176, 2016.

S. M. Matulis, V. A. Gupta, A. K. Nooka, H. V. Hollen, J. L. Kaufman et al., Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax, Leukemia, vol.30, pp.1086-93, 2016.

R. Bajpai, S. M. Matulis, C. Wei, A. K. Nooka, V. Hollen et al., Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax, Oncogene, vol.35, pp.3955-64, 2016.

S. Kumar, J. L. Kaufman, C. Gasparetto, J. Mikhael, R. Vij et al., Efficacy of venetoclax as targeted therapy for relapsed/ refractory t(11;14) multiple myeloma
URL : https://hal.archives-ouvertes.fr/inserm-01631468

C. Touzeau, L. Gouill, S. Mahé, B. Boudreault, J. S. Gastinne et al., Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14), Haematologica, vol.102, pp.112-116, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01445538

J. L. Kaufman, C. J. Gasparetto, J. Mikhael, P. Moreau, C. Touzeau et al., Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory multiple myeloma, Blood, vol.130, p.3131, 2017.

P. Moreau, A. Chanan-khan, A. W. Roberts, A. B. Agarwal, T. Facon et al., Promising efficacy and acceptable safety of C

, venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM, Blood, 2017.

M. A. Anderson, J. Deng, J. F. Seymour, C. Tam, S. Y. Kim et al., The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism, Blood, vol.127, pp.3215-3239, 2016.

J. Ryan and A. Letai, BH3 profiling in whole cells by fluorimeter or FACS, Methods San Diego Calif, vol.61, pp.156-64, 2013.

M. F. Van-delft, A. H. Wei, K. D. Mason, C. J. Vandenberg, L. Chen et al., The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, vol.10, pp.389-99, 2006.

M. Konopleva, R. Contractor, T. Tsao, I. Samudio, P. P. Ruvolo et al., Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer Cell, vol.10, pp.375-88, 2006.

D. C. Phillips, Y. Xiao, L. T. Lam, E. Litvinovich, L. Roberts-rapp et al., Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199), Blood Cancer J, vol.5, p.368, 2015.

P. Gomez-bougie, S. Wuillème-toumi, E. Ménoret, V. Trichet, N. Robillard et al., Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma, Cancer Res, vol.67, pp.5418-5442, 2007.

L. Zhou, Y. Zhang, D. Sampath, J. Leverson, Y. Dai et al., Flavopiridol enhances ABT-199 sensitivity in unfavourablerisk multiple myeloma cells in vitro and in vivo, Br J Cancer, vol.118, pp.388-97, 2018.

C. Dousset, S. Maïga, P. Gomez-bougie, L. Coq, J. Touzeau et al., BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01353369

S. K. Tahir, M. L. Smith, P. Hessler, L. R. Rapp, K. B. Idler et al., Potential mechanisms of resistance to venetoclax and strategies to circumvent it, BMC Cancer, vol.17, p.399, 2017.

V. A. Gupta, S. M. Matulis, J. E. Conage-pough, A. K. Nooka, J. L. Kaufman et al., Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma, Blood, vol.129, pp.1969-79, 2017.

V. Fresquet, M. Rieger, C. Carolis, M. J. García-barchino, and J. A. Martinezcliment, Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, pp.4111-4120, 2014.

C. D. Herling, N. Abedpour, J. Weiss, A. Schmitt, R. D. Jachimowicz et al., Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia, Nat Commun, vol.9, p.727, 2018.

S. Miguel, J. Weisel, K. Moreau, P. Lacy, M. Song et al., Pomalidomide plus low-dose dexamethasone versus highdose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, Lancet Oncol, vol.14, pp.1055-66, 2013.

M. A. Dimopoulos, P. Moreau, A. Palumbo, D. Joshua, L. Pour et al., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study, Lancet Oncol, vol.17, pp.27-38, 2016.

M. A. Dimopoulos, H. Goldschmidt, R. Niesvizky, J. D. Chng, W. J. Oriol et al., Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, pp.30578-30586

C. Fernández-de-larrea, R. A. Kyle, B. Durie, H. Ludwig, S. Usmani et al., Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, vol.27, pp.780-91, 2013.

B. Royer, S. Minvielle, M. Diouf, M. Roussel, L. Karlin et al., Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective Phase II Study of the Intergroupe Francophone du Myélome, J Clin Oncol J Am Soc Clin Oncol, vol.34, pp.2125-2157, 2016.

W. I. Gonsalves, F. K. Buadi, and S. K. Kumar, Combination therapy incorporating Bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14), Eur J Haematol, vol.100, pp.215-222, 2018.

A. Kotschy, Z. Szlavik, J. Murray, J. Davidson, A. L. Maragno et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, pp.477-82, 2016.

A. Hird, P. Secrist, A. Adam, and M. A. Belmonte, A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers, Cancer Res, vol.77, p.13, 2017.

P. E. Hughes, The discovery and preclinical characterization of AMG 176: a first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma, Cancer Res, vol.77, p.13, 2017.